Increase in transglutaminase 2 expression is associated with NF-κB activation in breast cancer tissues

Frontiers in Bioscience

Volumn 14, Issue 5, 2009, Pages 1945-1951

  Park, Kang Seo ^a   Kim, Dae Seok ^a   Jeong, Kyung Chae ^a   Kim, Soo Youl ^a  

^a National Cancer Center   (South Korea)

Author keywords

Breast cancer; I kappabalpha; NF kappaB; Review; Transglutaminase

Indexed keywords

GUANINE NUCLEOTIDE BINDING PROTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PROTEIN BAX; PROTEIN BCL 2; PROTEIN GLUTAMINE GAMMA GLUTAMYLTRANSFERASE; PROTEIN GLUTAMINE GAMMA GLUTAMYLTRANSFERASE 2; TUMOR PROTEIN;

ARTICLE; BREAST TUMOR; CHEMISTRY; ENZYMOLOGY; GEL MOBILITY SHIFT ASSAY; GENETICS; HUMAN; METABOLISM; MOLECULAR WEIGHT; PATHOLOGY;

BCL-2-ASSOCIATED X PROTEIN; BREAST NEOPLASMS; ELECTROPHORETIC MOBILITY SHIFT ASSAY; GTP-BINDING PROTEINS; HUMANS; MOLECULAR WEIGHT; NEOPLASM PROTEINS; NF-KAPPA B; PROTO-ONCOGENE PROTEINS C-BCL-2; TRANSGLUTAMINASES;

EID: 63849236973     PISSN: 27686701     EISSN: 27686698     Source Type: Journal    
DOI: 10.2741/3354     Document Type: Article

References (24)

1. Costantini V, Zacharski LR, Memoli VA, Kisiel W, Kudryk BJ, Rousseau SM. Fibrinogen deposition without thrombin generation in primary human breast cancer tissue. Cancer Res 51, 349-353 (1991).
2. Fettasch JM, Bandarenko N, Burchette JL, Lai TS, Marks JR, Haroon ZA, Peters K, Dewhirst MW, Iglehart JD, Greenberg CS. Tissue transglutaminase expression in human breast cancer. Lab Invest 75, 637-635 (1996).
3. Folk JE, Chung SI. Transglutaminases. Method in Enzymol 113, 358-375 (1985). (Pubitemid 16195806)
4. Kim SY. Transglutaminase in inflammation. Front Biosci 11, 3026-3035 (2006).
5. Chen JS, Agarwal N, Mehta K. Multidrug-resistant MCF-7 breast cancer cells contain deficient intracellular calcium pools. Breast Cancer Res Treat 71, 237-247 (2002). (Pubitemid 34263987)
6. Herman JF, Mangala LS, Mehta K. Implications of increased tissue transglutaminase (TG2) expression in drug-resistant breast cancer (MCF-7) cells. Oncogene 25, 3049-3058 (2006). (Pubitemid 43780469)
7. Mehta K, Fok J, Miller FR, Koul D, Sahin AA. Prognostic significance of tissue transglutaminase in drug resistant and metastatic breast cancer. Clin Cancer Res 10, 8086-8075 (2004).
8. Mangala LS, Arun B, Sahin AA, Mehta K. Tissue transglutaminase-induced alterations in extracellular matrix inhibit tumor invasion. Mol Cancer 4, 33-38 (2005).
9. Pahl HL. Activators and target genes of Rel/NF-κB transcription factors. Oncogene 18, 6853-6866 (1999).
10. Patel NM, Nozaki S, Shortle NH. Paclitaxel sensitivity of breast cancer cells with constitutively active NF-κB is enhanced by I-κBα super-repressor and parthenolide. Oncogene 19, 4159-4169 (2000).
11. Nakanishi C, Toi M. Nuclear factor-κB inhibitors as sensitizers to anticancer drugs. Nat Rev Cancer 5, 297-309 (2005). (Pubitemid 40488635)
12. Vinay T, Virginine B, Masahito I, Qiutang L, Inder MV. I-κBα Kinase-Independent I-κBα Degradation Pathway: Functional NF-B Activity and Implications for Cancer Therapy. Mol Cell Biol 23, 8070-8083 (2003).
13. Lee J, Kim YS, Choi DH, Bang MS, Han TR, Joh TH, Kim SY. Transglutaminase 2 induces nuclear factor-kappaB activation via a novel pathway in BV-2 microglia. J Biol Chem 279, 53725-53735 (2004). (Pubitemid 40051881)
14. Kim DS, Park SS, Nam BH, Kim IH, Kim SY. Reversal of Drug Resistance in Breast Cancer Cells by Transglutaminase 2 Inhibition and NF-κB Inactivation. Cancer Res 66, 10936-10943 (2006).
15. Martinez-Arribas F, Nunez-Villar MJ, Lucas AR, Tejerina A. Immunofluorometric study of Bcl-2 and Bax expression in clinical fresh tumor samples from breast cancer patients. Anticancer res 23, 565-568 (2003). (Pubitemid 36358452)
16. Tamatani M, Che YH, Matsuzaki H, Ogawa S, Okado H, Miyake SI, Mizuno T, Tohyamam M. Tumor Necrosis Factor Induces Bcl-2 and Bcl-x Expression through NFκB Activation in Primary Hippocampal Neurons. J Biol Chem 274, 8531-8538 (1999). (Pubitemid 29164643)
17. Fesus L, Szondy Z. Transglutaminase 2 in the balance of cell death and survival. FEBS Lett 579, 3297-3302 (2005). (Pubitemid 40804677)
18. Piacentini M, Farrace MG, Piredda L, Matarrese P, Ciccosanti F, Falasca L, Rodolfo C, Giammarioli AM, Verderio E, Griffin M, Malorni W. Transglutaminase overexpression sensitizes neuronal cell lines to apoptosis by increasing mitochondrial membrane potential and cellular oxidative stress. J Neurochem 81, 1061-1072 (2002). (Pubitemid 34809289)
19. Scott KF, Meyskens FL, Russell DH. Retinoids increase transglutaminase activity and inhibit ornithine decarboxylase activity in Chinese hamster ovary cells and in melanoma cells stimulated to differentiate. Proc Natl Acad Sci 79, 4093-4097 (1982). (Pubitemid 12035084)
20. Boehm JE, Singh U, Combs C, Antonyak MA, Cerione RA. Tissue transglutaminase protects against apoptosis by modifying the tumor suppressor protein p110 Rb. J Biol Chem 277, 20127-20130 (2002). (Pubitemid 34967301)
21. Yamaguchi H, Wang HG. Tissue transglutaminase serves as an inhibitor of apoptosis by cross-linking caspase 3 in thapsigargin-treated cells. Mol Cell Biol 26, 569-579 (2006). (Pubitemid 43089769)
22. Evqeny A, Zemskov, Anna J, Jun H, Anu W, Alexey MB. The role of tissue transglutaminase in cell-matrix interactions. Front Biosci 11, 1057-1076 (2006). (Pubitemid 43253460)
23. Patel NM, Nozaki S, Shortle NH, Bhat-Nakshatri P, Newton TR, Rics S, Gelfanov V, Boswell SH, Jr. Goulet RJ, Jr. Sledge GW, Nakshatri H. Paclitaxel sensitivity of breast cancer cells with constitutively active NF-κB is enhanced by I-κBα super-repressor and parttenolide. Oncogene 19, 4159-4169 (2000).
24. Han JA, Park SC. Reduction of transglutaminase 2 expression is associated with an induction of drug sensitivity in the PC-14 human lung cancer cell line. J Cancer Res Clin Oncol 125, 89-95 (1999). (Pubitemid 29161460)